FNT.U Stock Overview
Through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
FLUENT Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.055 |
| 52 Week High | US$0.25 |
| 52 Week Low | US$0.05 |
| Beta | 2.91 |
| 1 Month Change | -21.43% |
| 3 Month Change | -38.89% |
| 1 Year Change | -69.44% |
| 3 Year Change | -87.50% |
| 5 Year Change | -45.00% |
| Change since IPO | -97.18% |
Recent News & Updates
Recent updates
Slammed 29% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Dec 27
Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 07Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt
Oct 25Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward
Sep 04Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Jul 11Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story
Jan 15Is Cansortium (CSE:TIUM.U) Using Too Much Debt?
Nov 30Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?
Sep 01Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Jul 28An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Mar 08Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?
Jan 09Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden
Sep 09Shareholder Returns
| FNT.U | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.8% | -2.1% |
| 1Y | -69.4% | -45.5% | 9.6% |
Return vs Industry: FNT.U underperformed the Canadian Pharmaceuticals industry which returned -44.2% over the past year.
Return vs Market: FNT.U underperformed the Canadian Market which returned 11.1% over the past year.
Price Volatility
| FNT.U volatility | |
|---|---|
| FNT.U Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 12.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.2% |
Stable Share Price: FNT.U has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: FNT.U's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Robert Beasley | getfluent.com |
FLUENT Corp., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company’s medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products.
FLUENT Corp. Fundamentals Summary
| FNT.U fundamental statistics | |
|---|---|
| Market cap | US$16.54m |
| Earnings (TTM) | -US$19.71m |
| Revenue (TTM) | US$104.19m |
0.2x
P/S Ratio-0.8x
P/E RatioIs FNT.U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNT.U income statement (TTM) | |
|---|---|
| Revenue | US$104.19m |
| Cost of Revenue | US$44.07m |
| Gross Profit | US$60.12m |
| Other Expenses | US$79.83m |
| Earnings | -US$19.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.066 |
| Gross Margin | 57.70% |
| Net Profit Margin | -18.92% |
| Debt/Equity Ratio | -1,240.1% |
How did FNT.U perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/10 06:37 |
| End of Day Share Price | 2025/03/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FLUENT Corp. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Stanley | Beacon Securities Limited |
| Jonathan DeCourcey | BTIG |
| Robert Burleson | Canaccord Genuity |